KCL22-s/NF-kB Reporter (Luc) stable cell line

KCL22-s/NF-kB Reporter (Luc) cells are derived from human lymphoblast-like cell line KCL22-s by stably integration of a NF-kB firefly luciferase reporter construct. KCL22-s cells are a variant of the KCL22 cell line that is sensitive to imatinib, a tyrosine kinase inhibitor commonly used to treat chronic myeloid leukemia (CML) . Imatinib targets the BCR-ABL fusion protein, which is a key driver of CML. The paired KCL22-s and KCL22-r clones are useful cell line models of sensitivity and resistance to imatinib. KCL22-s/NF-kB Reporter (Luc) cells stably express firefly luciferase under the control of the NF-kB response elements, can be used for monitoring the activity of NF-kB signaling pathway.